Stephen H. Hitchcock

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.

H. Monenschein, S. Kikuchi, Nidhi Kaushal, 2021, Journal of medicinal chemistry.

Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia.

H. Monenschein, A. Amador-Arjona, J. Bliesath, 2021, Journal of medicinal chemistry.

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease

Justin Powell, H. Monenschein, S. Sheardown, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Target 2035 – update on the quest for a probe for every protein

G. A. Bezerra, T. Willson, G. Superti-Furga, 2021, RSC medicinal chemistry.